CAMP

Camp4 Therapeutics Corp (CAMP) - Q1 2025 10-Q Summary

Business Context and Reporting Period

Camp4 Therapeutics Corp is a clinical-stage biopharmaceutical company developing RNA-based therapeutics to treat genetic diseases. The company operates as a single segment focused on research and development (R&D). This report covers the quarterly period ended March 31, 2025. The company completed its Initial Public Offering (IPO) in October 2024 and is classified as an emerging growth company and a smaller reporting company.

Key Financial Metrics

Note: The filing does not provide explicit margin percentages due to the absence of product sales revenue and the nature of the pre-revenue biotech business model.

Material Changes vs. Prior Period

• Revenue Generation: The company recognized $0.9 million in research and collaboration revenue in Q1 2025, primarily from a new collaboration agreement with BioMarin Pharmaceutical Inc. entered in September 2024. No revenue was recognized in Q1 2024.
• Expense Growth: Total operating expenses increased by $1.1 million (8.4%) year-over-year.
  • R&D Expenses: Increased by $0.4 million to $10.1 million, driven by clinical trial costs for the lead candidate CMP-CPS-001 and increased professional fees.
  • G&A Expenses: Increased by $0.7 million to $3.8 million, attributed to personnel-related costs (salary increases and stock compensation) and higher insurance premiums.
• Net Loss: Net loss remained relatively flat at approximately $12.4 million, despite the revenue increase, due to higher operating costs.
• Per Share Impact: Net loss per share improved significantly from $(26.57) to $(0.62) due to the reverse stock split and IPO completed in late 2024, which increased the share count from ~469k to ~20.1 million.

Guidance, Outlook, and Risks

• Liquidity and Going Concern: As of March 31, 2025, the company held $49.3 million in cash. Management estimates this is sufficient to fund operations into the second quarter of 2026. However, the filing explicitly states this raises substantial doubt about the company's ability to continue as a going concern beyond the next 12 months without additional financing.
• Development Pipeline:
  • CMP-CPS-001 (Urea Cycle Disorders): Phase 1 clinical trial ongoing. Interim analysis of single ascending dose (SAD) completed with no safety concerns. Multiple ascending dose (MAD) dosing for first three cohorts completed. Data expected in Q4 2025.
  • CMP-SYNGAP-01 (SYNGAP1-related disorders): Preclinical development candidate nominated. GLP toxicology studies expected to initiate in 2025.
  • GBA1 (Parkinson's Disease): Discovery program initiated.
• Collaborations:
  • BioMarin: Recognized $0.9 million revenue in Q1 2025. Agreement includes potential milestones up to $185 million and royalties.
  • Fulcrum Therapeutics: Subsequent event noted a $0.6 million milestone payment recognized in April 2025.
• Risks: Key risks include the need for additional capital, reliance on third-party manufacturers, regulatory approval uncertainties, and potential impacts of international trade policies and tariffs on supply chain costs.

Investor Verification Checklist

• Cash Runway: Verify the specific burn rate assumptions used to project cash sufficiency into Q2 2026 and the timeline for potential capital raises.
• BioMarin Revenue Recognition: Confirm the cost-to-cost methodology used for recognizing the $3.8 million transaction price over time.
• Clinical Trial Progress: Monitor the Q4 2025 data readout for CMP-CPS-001, specifically safety and pharmacodynamic biomarker results.
• Going Concern Status: Assess the company's ability to secure additional funding before the projected cash depletion in mid-2026.
• Subsequent Events: Note the $0.6 million milestone revenue recognized in April 2025 from the Fulcrum agreement and its impact on Q2 2025 results.